Studies show that enhancing NK cell activity to impede tumor growth can be achieved through the use of PD-1/PD-L1 inhibitors, offering a promising strategy for ICB therapy.74,75 Given the intricate mechanisms of tumor evasion from the immune system and the considerable heterogeneity across tumor types, it is advisable that immune profiling techniques encompass not only cytotoxic CD8+ T cells but also NK cells. Here, CD8A is linked to neoplasm.